Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — FY2017 Earnings Presentation
10 slides from Angiodynamics's earnings presentation, Jul 18, 2017
Slide 1: Fiscal 2017 Fourth Quarter and Full-Year Earnings Presentation
AngioDynamics Fiscal 2017 Fourth Quarter and Full-Year Earnings Presentation July 18, 2017 ® angiodynamics
Slide 2: Safe Harbor and Non-GAAP Statement
Safe Harbor and Non-GAAP Statement Cautionary Notice Regarding Forward Looking Statements ‘This release contains fonvardlookng statements within the mearing of the Private Seoutes itgation Reform Act of 1995, Alstatements regarding AngioDynamios' expected future financial postin, results of operatio
Slide 3: FY2017 Highlights
FY2017 Highlights Company had record high adjusted EPS of $0.73 and Free Cash Flow of $52.7 million Revenue of$249.6 millon included $26 milion reserve related to recall and voluntary market withdrawalof Acculls ‘Adjusted EPS of $0.73, up 22% compared to FY2016 Generated $527 milion in free cash flo
Slide 4: FY2017 Q4 and Full-Year Results
FY2017 Q4 and Full-Year Results FY2017 FY2016 FY2017 FY2016 Full Year Full Year Sinmilions(exceptpershare) __@Q4Results _—Q4Results_ Change _ Results Results Change Revenue $86.9 $93.4 (1% $349.6 $353.9 (1)% Peripheral. Vascular 540 556 @% 2086 2056 1% =Vascular Access. 242 248 2% 64 994 @% ry ology
Slide 5: Impact of Significant FY2017 Events
Impact of Significant FY2017 Events Revenue Earnings $ in mitions Impact Impact ‘Acculis Recall and Market Withdrawal ($2.6) ($4.5) - Reserve for in-market Acculis probes returned due to recall (62.6) ($1.9) - Inventory Reserve for Acculis probes and generators* ($2.6) Asset/Liability Write-Offs* An
Slide 6: FY2018 Guidance
FY2018 Guidance FY2017 Actuals FY2018 Guidance Revenue $349.6m $352-$359m Adjusted EPS $0.73 $0.64-$0.68 $52.7m $35m+ Free Cash Flow FOCUS | EXECUTION | ACCOUNTABILITY ® angiodynamics
Slide 7: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation ® angiodynamics
Slide 8: Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS
Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS con ee en CAP ted a Pt ® angiodynamics
Slide 9: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS ‘Three months ended ‘Twelve months ended May 31 May 31 May 31 May 31, 2017 2016 2017 2016 (Unaudited) (Graudied) s Net income (loss) (10913) $43,075) $S 7.008 $149,590) Income tax expense 85 40.253 4g99 40.337 Interest expense 689 789 2.860
Slide 10: Growth through Focus | Execution | Accountability
Growth through Focus | Execution | Accountablity ®D angiodyna